185 related articles for article (PubMed ID: 24163335)
21. Characterization of Pseudomonas aeruginosa enoyl-acyl carrier protein reductase (FabI): a target for the antimicrobial triclosan and its role in acylated homoserine lactone synthesis.
Hoang TT; Schweizer HP
J Bacteriol; 1999 Sep; 181(17):5489-97. PubMed ID: 10464225
[TBL] [Abstract][Full Text] [Related]
22. Resistance to AFN-1252 arises from missense mutations in Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI).
Yao J; Maxwell JB; Rock CO
J Biol Chem; 2013 Dec; 288(51):36261-71. PubMed ID: 24189061
[TBL] [Abstract][Full Text] [Related]
23. Triclosan resistance of Pseudomonas aeruginosa PAO1 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductase.
Zhu L; Lin J; Ma J; Cronan JE; Wang H
Antimicrob Agents Chemother; 2010 Feb; 54(2):689-98. PubMed ID: 19933806
[TBL] [Abstract][Full Text] [Related]
24. Expression, purification and characterization of enoyl-ACP reductase II, FabK, from Porphyromonas gingivalis.
Hevener KE; Mehboob S; Boci T; Truong K; Santarsiero BD; Johnson ME
Protein Expr Purif; 2012 Sep; 85(1):100-8. PubMed ID: 22820244
[TBL] [Abstract][Full Text] [Related]
25. Biochemical and Structural Basis of Triclosan Resistance in a Novel Enoyl-Acyl Carrier Protein Reductase.
Khan R; Zeb A; Roy N; Thapa Magar R; Kim HJ; Lee KW; Lee SW
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29891603
[TBL] [Abstract][Full Text] [Related]
26. Crystal structure of enoyl-acyl carrier protein reductase (FabK) from Streptococcus pneumoniae reveals the binding mode of an inhibitor.
Saito J; Yamada M; Watanabe T; Iida M; Kitagawa H; Takahata S; Ozawa T; Takeuchi Y; Ohsawa F
Protein Sci; 2008 Apr; 17(4):691-9. PubMed ID: 18305197
[TBL] [Abstract][Full Text] [Related]
27. Atromentin and leucomelone, the first inhibitors specific to enoyl-ACP reductase (FabK) of Streptococcus pneumoniae.
Zheng CJ; Sohn MJ; Kim WG
J Antibiot (Tokyo); 2006 Dec; 59(12):808-12. PubMed ID: 17323650
[TBL] [Abstract][Full Text] [Related]
28. Characterization of FabG and FabI of the Streptomyces coelicolor dissociated fatty acid synthase.
Singh R; Reynolds KA
Chembiochem; 2015 Mar; 16(4):631-40. PubMed ID: 25662938
[TBL] [Abstract][Full Text] [Related]
29. The enoyl-[acyl-carrier-protein] reductases FabI and FabL from Bacillus subtilis.
Heath RJ; Su N; Murphy CK; Rock CO
J Biol Chem; 2000 Dec; 275(51):40128-33. PubMed ID: 11007778
[TBL] [Abstract][Full Text] [Related]
30. FabV, the Unique Enoyl-Acyl Carrier Protein Reductase in
Li F; Deng J; Zhang Z; Wang C; Mao Y
Phytopathology; 2024 Apr; 114(4):780-791. PubMed ID: 37913555
[TBL] [Abstract][Full Text] [Related]
31. Discovery of a novel and potent class of FabI-directed antibacterial agents.
Payne DJ; Miller WH; Berry V; Brosky J; Burgess WJ; Chen E; DeWolf WE; Fosberry AP; Greenwood R; Head MS; Heerding DA; Janson CA; Jaworski DD; Keller PM; Manley PJ; Moore TD; Newlander KA; Pearson S; Polizzi BJ; Qiu X; Rittenhouse SF; Slater-Radosti C; Salyers KL; Seefeld MA; Smyth MG; Takata DT; Uzinskas IN; Vaidya K; Wallis NG; Winram SB; Yuan CC; Huffman WF
Antimicrob Agents Chemother; 2002 Oct; 46(10):3118-24. PubMed ID: 12234833
[TBL] [Abstract][Full Text] [Related]
32. Meleagrin, a new FabI inhibitor from Penicillium chryosogenum with at least one additional mode of action.
Zheng CJ; Sohn MJ; Lee S; Kim WG
PLoS One; 2013; 8(11):e78922. PubMed ID: 24312171
[TBL] [Abstract][Full Text] [Related]
33. Biochemical and structural characterization of the trans-enoyl-CoA reductase from Treponema denticola.
Bond-Watts BB; Weeks AM; Chang MC
Biochemistry; 2012 Aug; 51(34):6827-37. PubMed ID: 22906002
[TBL] [Abstract][Full Text] [Related]
34. Crystallization and preliminary X-ray analysis of enoyl-acyl carrier protein reductase (FabK) from Streptococcus pneumoniae.
Saito J; Yamada M; Watanabe T; Kitagawa H; Takeuchi Y
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2006 Jun; 62(Pt 6):576-8. PubMed ID: 16754986
[TBL] [Abstract][Full Text] [Related]
35. Biochemical and Structural Insights Concerning Triclosan Resistance in a Novel YX
Khan R; Zeb A; Choi K; Lee G; Lee KW; Lee SW
Sci Rep; 2019 Oct; 9(1):15401. PubMed ID: 31659200
[TBL] [Abstract][Full Text] [Related]
36. Structural and biochemical characterization of FabK from Thermotoga maritima.
Ha BH; Shin SC; Moon JH; Keum G; Kim CW; Kim EE
Biochem Biophys Res Commun; 2017 Jan; 482(4):968-974. PubMed ID: 27908729
[TBL] [Abstract][Full Text] [Related]
37. FabI (enoyl acyl carrier protein reductase) - A potential broad spectrum therapeutic target and its inhibitors.
Rana P; Ghouse SM; Akunuri R; Madhavi YV; Chopra S; Nanduri S
Eur J Med Chem; 2020 Dec; 208():112757. PubMed ID: 32883635
[TBL] [Abstract][Full Text] [Related]
38. The genome of a Bacteroidetes inhabitant of the human gut encodes a structurally distinct enoyl-acyl carrier protein reductase (FabI).
Radka CD; Frank MW; Yao J; Seetharaman J; Miller DJ; Rock CO
J Biol Chem; 2020 May; 295(22):7635-7652. PubMed ID: 32317282
[TBL] [Abstract][Full Text] [Related]
39. The use of a hybrid genetic system to study the functional relationship between prokaryotic and plant multi-enzyme fatty acid synthetase complexes.
Kater MM; Koningstein GM; Nijkamp HJ; Stuitje AR
Plant Mol Biol; 1994 Aug; 25(5):771-90. PubMed ID: 8075395
[TBL] [Abstract][Full Text] [Related]
40. Aquastatin A, a new inhibitor of enoyl-acyl carrier protein reductase from Sporothrix sp. FN611.
Kwon YJ; Fang Y; Xu GH; Kim WG
Biol Pharm Bull; 2009 Dec; 32(12):2061-4. PubMed ID: 19952429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
